Progress of EB virus related post-transplantation lymphoproliferative diseases / 白血病·淋巴瘤

ABSTRACT

Epstein-Barr virus (EBV) related post-transplant lymphoproliferative diseases (EBV-PTLD) is a rare and deadly complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The clinical manifestations often show the unexplained fever, swollen lymph nodes, hepatosplenomegaly, pharyngitis, and central nervous system symptoms, with rapid disease progression and high fatality rate. As allo-HSCT for treatment of complex and refractory hemopathy has made a great progress, the prevention of graft versus host disease (GVHD) requires more application of immune inhibitors, resulting in an increasing incidence rate of PTLD. In addition to conventional treatments, such as antiviral therapy, reduction of immune suppression , local surgery and traditional chemotherapy, monoclonal antibodies and adoptive immunotherapy with T-cells for treatment of PTLD have brought a profound influence. This paper reviews the latest progress of treatment of EBV-PTLD.